GENE EDITING 101
All Companies
🇺🇸

Tune Therapeutics

Private

Tuning genes without cutting DNA

Tune Therapeutics develops epigenome editing therapies that modulate gene expression without altering DNA sequences. Their platform uses programmable epigenome editors to durably silence or activate genes, offering an alternative to traditional gene editing with potentially improved safety profiles.

Founded2020
HQDurham, NC / with European operations
CEOMichael Gao
StatusPrivate
Total Funding$300M

Pipeline

Drug / ProgramIndicationPhaseTechnology
TUNE-401Chronic Hepatitis BPreclinicalEpigenome Editing

Key People

Michael GaoCEO
Charles GersbachCo-founder

Related Articles

CRISPR Companies to Watch in 2026: Who's Leading the Gene Editing Revolution?
Biotech Companies
Market Analysis

CRISPR Companies to Watch in 2026: Who's Leading the Gene Editing Revolution?

A comprehensive look at the CRISPR companies shaping the future of medicine in 2026, from approved therapies to next-generation editing platforms.

Mar 16, 20266 min read